- Home
- AKRO
as 04-18-2025 1:30pm EST
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.8B | IPO Year: | 2019 |
| Target Price: | $76.29 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.86 - $58.40 | Next Earning Date: | 05-09-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Akero Therapeutics Inc. (AKRO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Yale Catriona | AKRO | Chief Development Officer | Apr 15 '25 | Sell | $38.21 | 9,073 | $343,962.22 | 95,034 | |
| Cheng Andrew | AKRO | President and CEO | Apr 10 '25 | Sell | $35.23 | 30,000 | $1,056,780.00 | 624,324 | |
| Rolph Timothy | AKRO | Chief Scientific Officer | Apr 7 '25 | Sell | $36.56 | 6,250 | $224,261.50 | 169,921 | |
| Graham G. Walmsley | AKRO | Director | Mar 25 '25 | Buy | $43.77 | 200,000 | $8,787,921.11 | 1,200,000 | |
| Yale Catriona | AKRO | Chief Development Officer | Mar 17 '25 | Sell | $44.87 | 10,000 | $447,605.05 | 95,034 | |
| White William Richard | AKRO | Chief Financial Officer | Mar 12 '25 | Sell | $44.88 | 676 | $30,338.88 | 61,959 | |
| Yale Catriona | AKRO | Chief Development Officer | Mar 12 '25 | Sell | $44.88 | 614 | $27,556.32 | 95,034 | |
| Young Jonathan | AKRO | Chief Operating Officer | Mar 12 '25 | Sell | $44.88 | 607 | $27,242.16 | 200,540 | |
| Cheng Andrew | AKRO | President and CEO | Mar 12 '25 | Sell | $44.88 | 1,738 | $78,001.44 | 624,324 | |
| Rolph Timothy | AKRO | Chief Scientific Officer | Mar 12 '25 | Sell | $44.88 | 516 | $23,158.08 | 169,921 |
Latest Akero Therapeutics Inc. News
AKRO Breaking Stock News: Dive into AKRO Ticker-Specific Updates for Smart Investing
MT Newswires
22 days ago
Akero Therapeutics Insider Bought Shares Worth $8,787,921, According to a Recent SEC Filing
MT Newswires
a month ago
Akero Therapeutics Insider Sold Shares Worth $2,243,213, According to a Recent SEC Filing
Zacks
2 months ago
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?
Insider Monkey
2 months ago
Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025
MT Newswires
2 months ago
Akero Therapeutics Q4 Loss Unchanged
GlobeNewswire
2 months ago
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Insider Monkey
2 months ago
Is Akero Therapeutics Inc. (AKRO) the Best Performing Mid Cap Stock to Buy According to Analysts?
Insider Monkey
2 months ago
Akero Therapeutics, Inc. (AKRO): the Best Performing Pharma Stock So Far in 2025
Compare AKRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKRO Akero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.